Blonanserin Augmentation of Atypical Antipsychotics in Patients with Schizophrenia-Who Benefits from Blonanserin Augmentation?: An Open-Label, Prospective, Multicenter Study

Psychiatry Investigation
Young Sup WooWon-Myong Bahk

Abstract

The purpose of this study was to investigate the efficacy and tolerability of atypical antipsychotics (AAPs) with augmentation by blonanserin in schizophrenic patients. aA total of 100 patients with schizophrenia who were partially or completely unresponsive to treatment with an AAP were recruited in this 12-week, open-label, non-comparative, multicenter study. Blonanserin was added to their existing AAP regimen, which was maintained during the study period. Efficacy was primarily evaluated using the Positive and Negative Syndrome Scale (PANSS) at baseline and at weeks 2, 4, 8, and 12. Predictors for PANSS response (≥20% reduction) were investigated. The PANSS total score was significantly decreased at 12 weeks of blonanserin augmentation (-21.0±18.1, F=105.849, p<0.001). Moreover, 51.0% of participants experienced a response at week 12. Premature discontinuation of blonanserin occurred in 17 patients (17.0%); 4 of these patients dropped out due to adverse events. The patients who benefited the most from blonanserin were those with severe symptoms despite a treatment with a higher dose of AAP. Blonanserin augmentation could be an effective strategy for patients with schizophrenia who were partially or completely unresponsive to...Continue Reading

References

Oct 1, 1994·The American Journal of Psychiatry·J D HegartyG Oepen
Feb 2, 1999·The British Journal of Psychiatry : the Journal of Mental Science·J L WaddingtonA Kinsella
Oct 9, 2002·Acta Psychiatrica Scandinavica·S M Stahl
Oct 9, 2002·Acta Psychiatrica Scandinavica·Oliver Freudenreich, D C Goff
Sep 4, 2004·Psychiatric Services : a Journal of the American Psychiatric Association·Leslie CitromeJames Robinson
Sep 21, 2005·The New England Journal of Medicine·Jeffrey LiebermanClinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators
Sep 22, 2005·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Peter FalkaiWFSBP Task Force on Treatment Guidelines for Schizophrenia
Feb 2, 2006·The British Journal of Psychiatry : the Journal of Mental Science·Matti JoukamaaVille Lehtinen
Feb 3, 2006·The New England Journal of Medicine·William G HonerClozapine and Risperidone Enhancement (CARE) Study Group
Feb 17, 2006·Schizophrenia Bulletin·Brian KirkpatrickStephen R Marder
Oct 31, 2006·Schizophrenia Research·Christoph U CorrellPeter Manu
Nov 10, 2006·Journal of Psychopharmacology·Jenifer Chan, Melinda Sweeting
Mar 6, 2007·Schizophrenia Research·Marc De HertJoseph Peuskens
Jan 30, 2008·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Marc VermeirAdriaan Cleton
Dec 6, 2008·Journal of Psychiatric Practice·Anand K Pandurangi, Alican Dalkilic
Dec 4, 2009·Schizophrenia Bulletin·Robert W BuchananSchizophrenia Patient Outcomes Research Team (PORT)
Dec 25, 2009·CNS Drugs·Emma D Deeks, Gillian M Keating
Apr 3, 2010·The American Journal of Psychiatry·David M GardnerRoss J Baldessarini
Jul 29, 2010·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Elaine WeinerRobert W Buchanan
Feb 25, 2011·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Joseph I FriedmanSaurabh Kaushik
Apr 12, 2011·CNS Drugs·Thomas R E Barnes, Carol Paton
Nov 15, 2011·Acta Psychiatrica Scandinavica·D M TaylorJ Nielsen
Jun 22, 2012·The International Journal of Neuropsychopharmacology·W Wolfgang Fleischhacker, Hiroyuki Uchida
Jul 28, 2012·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Alkomiet HasanWorld Federation of Societies of Biological Psychiatry (WFSBP) Task Force on Treatment Guidelines for Schizophrenia
Dec 12, 2012·Schizophrenia Research·Handan Gunduz-BruceGeorgios Petrides
Feb 16, 2013·Journal of Psychopharmacology·Marc W H Lochmann van BennekomFrans G Zitman
Jun 15, 2013·Neuropsychiatric Disease and Treatment·Tomomi TenjinNoboru Yamaguchi
Jun 19, 2013·Journal of Clinical Psychopharmacology·Janique G JessurunDiederik E Tenback
Sep 6, 2014·Clinical Psychopharmacology and Neuroscience : the Official Scientific Journal of the Korean College of Neuropsychopharmacology·Hee-Yun KimChul-Eung Kim
Dec 1, 2012·Acta Neuropsychiatrica·Manabu TakakiYosuke Uchitomi

Citations

Jul 30, 2019·Clinical Psychopharmacology and Neuroscience : the Official Scientific Journal of the Korean College of Neuropsychopharmacology·Young Sup WooWon-Myong Bahk

Related Concepts

Schizophrenia
Antipsychotic Agents
Treatment Protocols
Blonanserin
Discontinuation (Procedure)
Participant
Adverse Event
Multicenter Study
Augmentation Procedure
Health Care Organization

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here